Institute for Quality and Efficiency in Health Care

Medications

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Cardiology

Coronary heart disease: DMP could be extended by two topics

Disease management programmes (DMPs) must be updated at regular intervals to adapt them to the current state of medical knowledge. The German Institute for Quality and Efficiency in Health Care (IQWiG) therefore searched ...

Medications

Aflibercept in diabetic macular oedema: Added benefit not proven

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care (IQWiG) examined ...

Medications

Added benefit of vedolizumab is not proven

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

page 5 from 29